Business Description
argenx SE
ISIN : NL0010832176
Compare
Compare
Traded in other countries / regions
ARGX.USAARGX.Belgium0QW0.UK1AE.GermanyARGX.AustriaA1RG34.BrazilARGX.Mexico IPO Date
2014-07-11Description
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 158.99 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 30.17 | |||||
| Beneish M-Score | -1.02 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 197.5 | |||||
| 3-Year EBITDA Growth Rate | 34.3 | |||||
| 3-Year EPS without NRI Growth Rate | 17.8 | |||||
| 3-Year FCF Growth Rate | -0.6 | |||||
| 3-Year Book Growth Rate | 29.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -231.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 40.73 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.3 | |||||
| 9-Day RSI | 32.02 | |||||
| 14-Day RSI | 37.78 | |||||
| 6-1 Month Momentum % | -26.2 | |||||
| 12-1 Month Momentum % | -3.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.75 | |||||
| Quick Ratio | 9.01 | |||||
| Cash Ratio | 7.52 | |||||
| Days Inventory | 764.05 | |||||
| Days Sales Outstanding | 95.47 | |||||
| Days Payable | 649.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.6 | |||||
| Shareholder Yield % | -0.02 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 90.39 | |||||
| Operating Margin % | -34.29 | |||||
| Net Margin % | -24.03 | |||||
| FCF Margin % | -37.45 | |||||
| ROE % | -9.05 | |||||
| ROA % | -8.13 | |||||
| ROIC % | -44.84 | |||||
| ROC (Joel Greenblatt) % | -85.05 | |||||
| ROCE % | -9.29 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 17.05 | |||||
| PB Ratio | 5.32 | |||||
| Price-to-Tangible-Book | 5.48 | |||||
| EV-to-EBIT | -60.59 | |||||
| EV-to-Forward-EBIT | -58.33 | |||||
| EV-to-EBITDA | -60.59 | |||||
| EV-to-Forward-EBITDA | -60.09 | |||||
| EV-to-Revenue | 15.03 | |||||
| EV-to-Forward-Revenue | 10.2 | |||||
| EV-to-FCF | -40.8 | |||||
| Price-to-Net-Current-Asset-Value | 5.92 | |||||
| Price-to-Net-Cash | 7.96 | |||||
| Earnings Yield (Greenblatt) % | -1.65 | |||||
| FCF Yield % | -2.12 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers